Is More Downside Ahead For Teva Pharmaceutical?

Less than a week has gone by since Teva Pharmaceutical Industries ( TEVA ) announced the sudden departure of CEO Erez Vigodman , the latest in a string of stock price-depleting news for the generic drug giant. The U.S.-listed shares have fallen more than 40% over the past 12 months to a recent $32.32. But analysts at Mizuho Securities see more downside for Teva